April 2021

In the next issue of Pharma Technology Focus, we dive into the online world of social media marketing to learn how pharma companies are adapting to the growing prominence of digital platforms. Plus, we take a look at recent collaborations between Big Pharma and Big Tech and what pooling resources from two powerhouse industries could mean for the future of medicine.

Elsewhere, as vaccines indicate a light at the end of the Covid-19 tunnel we turn our attention to the next pandemic to find out how we can avoid healthcare disasters in the future, examine changing attitudes to chronic fatigue care, and investigate a new regulatory framework for the production, distribution, and export of medical cannabis on the Isle of Man.

Also, we examine the transformative potential of mRNA-based vaccines, speaks to the minds behind the Ineos Oxford Institute for AMR Research, and learn how pharma companies have been embracing the public benefit corporation model.

EDITORIAL

Editor | Eloise McLennan

Commissioning Editor| Daniel Garrun

Writers | Allie Nawrat, Natalie Healey, Abi Millar, Chloe Kent, Peter Kohut
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Petra Konyi-Kiss, Maria Gimenez, Filipe Costa, Martina Labaiova
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Getting the skinny on generics labellingGo to article: In this issueGo to article: ContentsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: The Solubility companyGo to article: The Solubility Company Insight Go to article: CommentGo to article: Market access of orphan designated therapies at riskGo to article: Lodo Therapeutics’ AI-driven natural drug discovery platformGo to article: Concert Pharmaceuticals discontinues schizophrenia drug after trial failureGo to article: Medical cannabis in Europe: a compelling opportunityGo to article: Exploring the pharma deals outlook in 2021Go to article: In DepthGo to article: Skinny labelling of generics: the beginning of the end for this practice?Go to article: Charting the choppy history of ‘magic bullet’ antibody-drug conjugates Go to article: How a sleeping drug awakened a patient with akinetic mutismGo to article: Breast cancer research: addressing the pre-menopausal problemGo to article: Beyond the lung: treating the GI symptoms of Covid-19Go to article: Immortal cells and informed consent: the legacy of Henrietta LacksGo to article: How radiopharmaceuticals are helping fight cancer with Fusion Go to article: Competition heats up as new HIV prevention drug shows promise Go to article: BaxterGo to article: ACG WorldwideGo to article: In DataGo to article: Inside the dealGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue